BioCryst Pharmaceuticals Inc
NASDAQ:BCRX

Watchlist Manager
BioCryst Pharmaceuticals Inc Logo
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Watchlist
Price: 7.64 USD 0.92%
Market Cap: 1.6B USD
Have any thoughts about
BioCryst Pharmaceuticals Inc?
Write Note

BioCryst Pharmaceuticals Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BioCryst Pharmaceuticals Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Gross Profit
$404.6m
CAGR 3-Years
56%
CAGR 5-Years
109%
CAGR 10-Years
36%
Abbvie Inc
NYSE:ABBV
Gross Profit
$37.3B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Gross Profit
$22B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Gross Profit
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Gross Profit
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Gross Profit
$12B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
17%
No Stocks Found

BioCryst Pharmaceuticals Inc
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

BioCryst Pharmaceuticals Inc., a beacon in the realm of niche biopharmaceutical innovations, has carved its path by focusing on the development of novel oral drugs that address rare and serious medical conditions. Anchored by its expertise in small molecule therapies, BioCryst operates at the intricate intersection of biology and chemistry, designing drugs that intervene in essential biological pathways. Its flagship product, ORLADEYO® (berotralstat), received a significant nod of approval when it was launched as the first oral, once-daily prophylactic treatment for hereditary angioedema (HAE). This rare condition, characterized by recurrent swelling attacks, previously had limited treatment options, often requiring cumbersome and painful injections. The oral nature of ORLADEYO filled a critical unmet need, propelling the company to a lucrative frontier within the pharmaceutical market. Revenue generation for BioCryst is firmly rooted in the licensing and sale of its proprietary drugs. With ORLADEYO, the company has not only achieved a foothold in a specialty pharmaceutical market but also laid a foundation for sustainable financial growth. Through strategic pricing and distribution channels, supported by collaboration with global healthcare partners, BioCryst maximizes its market reach while focusing on adding to its pipeline with promising candidates in various stages of clinical development. Its approach is a careful blend of scientific innovation and business acumen, ensuring that the impacts of their breakthroughs are not only felt in prolonged patient lifespans but also reflected in the company’s bottom line.

BCRX Intrinsic Value
12.3 USD
Undervaluation 38%
Intrinsic Value
Price

See Also

What is BioCryst Pharmaceuticals Inc's Gross Profit?
Gross Profit
404.6m USD

Based on the financial report for Sep 30, 2024, BioCryst Pharmaceuticals Inc's Gross Profit amounts to 404.6m USD.

What is BioCryst Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
36%

Over the last year, the Gross Profit growth was 30%. The average annual Gross Profit growth rates for BioCryst Pharmaceuticals Inc have been 56% over the past three years , 109% over the past five years , and 36% over the past ten years .

Back to Top